Report of the Fifth Teaching Institute, Association of American Medical Colleges, by Helen H. Leeand Robert J. Glaser, editors. 262 pages, illustrated. Evanston, Ill., Association of American Medical Colleges, 1958. Cloth $5.00, paper $2.00
Between October 2012 and October 2015, we conducted a community trial to assess the impact of semi-annual (twice yearly) community treatment with albendazole on lymphatic filariasis in Seke Pembe, a village in the Republic of the Congo. Semi-annual community treatment with albendazole has been continued in the community since October 2015. We conducted an additional parasitological assessment survey in October 2019, 6 months after the 14th round of semi-annual treatment. Between October 2012 and October 2015, Wuchereria bancrofti antigenemia and microfilaremia rates in the community had decreased from 17.3% to 4.7% and from 5.3% to 0.3%, respectively. In October 2019, the antigenemia rate had decreased further to 2.8% (19 of 687). No microfilariae were found in night blood smears from persons with circulating filarial antigenemia (0 of 16), suggesting that W. bancrofti transmission has been interrupted in Seke Pembe. Semi-annual albendazole treatments also reduced significantly infection rates with soil-transmitted helminths.
Address correspondence to Sébastien D. S. Pion, IRD, 911 Av Agropolis, BP 64501, 34394 Montpellier Cedex 5, France. E-mail: firstname.lastname@example.org
These authors contributed equally to this work.
Authors’ addresses: Sébastien D. S. Pion, Cédric B. Chesnais, and Michel Boussinesq, Institut de Recherche pour le Développement, UMI233/INSERM U1175/Université de Montpellier, Montpellier, France, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com. Gary J. Weil, Infectious Diseases Division, Washington University School of Medicine, St. Louis, MO, E-mail: firstname.lastname@example.org. Frédéric Louya and François Missamou, Programme National de Lutte contre l’Onchocercose, Direction de l’Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of Congo, E-mails: XXXXX and email@example.com.